Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dynavax Technologies Corporation (DVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
11.18+1.56 (+16.22%)
At close: 04:00PM EDT
11.15 -0.03 (-0.27%)
After hours: 07:10PM EDT
Advertisement
Sign in to post a message.
  • E
    EC
    Clover approval adds $8-12, Valneva approval adds another $5-8. That puts DVAX at approximately $25-$30. If merger is before the winter, DVAX gets taken out at around $55. If no deal by the winter (where another Covid outbreak is likely to happen) where billions of ppl or more will get vaccines with the new 1018 adjuvant vaccine, DVAX could be $120 in the best case scenario and GSK can keep on selling its antique Engerix B.
  • E
    EC
    Biotechs enter bear market 4 months before Nasdaq and other indices. And it is expected to lead other markets out of the bear market. Expecting a nice lift from this ocean floor. Runway to merger is all clear. Expect a merger within 3 months when DVAX reaches $20’s.
  • E
    EC
    Expecting good news from Clover(2197.HK). China needs a new generation of homegrown Covid-19 vaccine and Clover is their only hope. Otherwise China will continue to have major shutdowns from city to city every few months. Clover will be a monopoly in China and DVAX will stand to benefit. If timing is right where Cover gets approved now or during next lockdown on the cities, both Clover and DVAX may trade as much #$%$10 times their current price by Winter time as Covid is certain to strike again. But I am afraid DVAX would be taken out long before Covid peaks again the coming winter.With Clover, China can resume their vaccine diplomacy cuz most countries around the world lack the delivery/storage infrastructure for MRNA vaccines. Besides china, there is also India and Vietnam racing to produce a new effective vaccine that can be deployed to developing and undeveloped countries. No matter with players came out first, they are using DVAX?s adjuvant so DVAX will always be a winner.
  • R
    RogerR
    Heplisav better and less expensive than the 3-dose options.

    Adult immunization against hepatitis B: Does the number of jabs matter?
    DOI: 10.1016/j.vaccine.2022.04.080
     
    Abstract
    Background: At least one-half of adults beginning an immunization series with a three-dose hepatitis B virus (HBV) vaccine (ENGERIX-B, RECOMBIVAX-B) have been reported not to receive the third dose. Use of a two-dose vaccine may improve adherence and lead to greater overall levels of seroprotection.
    Objective: To examine expected levels of adherence and overall seroprotection at one year among adults in routine clinical settings beginning an immunization series with either ENGERIX-B or the two-dose HBV vaccine, HEPLISAV-B.
    Methods: Decision-analytic model comparing expected levels of adherence and overall seroprotection at one year among a hypothetical cohort of one million previously unvaccinated adults aged ≥ 30 years receiving first doses of either ENGERIX-B or HEPLISAV-B in a routine clinical setting. We stratified the population by age (30-49 years vs ≥ 50 years) to allow for possible differences in adherence and seroprotection. We estimated our model using published adherence rates for HBV vaccines, and reported seroprotection rates by number of doses administered. We also compared total expected costs of HBV immunization with each vaccine.
    Results: Use of a two-dose rather than three-dose HBV vaccine would increase the expected number of adults seroprotected at one year by 275,000 per one million persons beginning immunization series, largely reflecting a gain of 290,000 in the expected number of persons fully vaccinated. Results were similar for the two age groups. While the cost per dose of HEPLISAV-B exceeds that of ENGERIX-B, its estimated mean cost per person seroprotected at one year is $50-$70 (∼15%) lower.
    Conclusions: Use of a two-dose HBV vaccine would increase the number of adults fully seroprotected at one year compared with the number expected with a three-dose vaccine. Notwithstanding its higher unit cost, mean expected cost per person seroprotected is substantially lower for HEPLISAV-B than ENGERIX-B as a result of much higher levels of seroprotection.
  • W
    William
    So do we have a "good news" leak regarding Clover causing this rally or simply nervous shorts after reading the Valneva news?
  • G
    Glenn
    I suspect there is something much larger than next week's Investor meeting....
  • D
    D
    JUST IN: 🇺🇸 The SEC has seized over 100 cellphones from Wall Street personnel to investigate insider trading. Well...better late than never. Hopefully this leads to a brand new awoken financial dawn free of manipulation to help the average retail investor get ahead. Enough BS. Go #Dvax and rise like you should!
    Bullish
  • A
    A1
    Vote NO...Next Week...If They Can Do It We Can...

    JPMorgan Chase shareholders reject options bonus for CEO Jamie Dimon...

    He doesn't deserve a Dime...

    GL

    A1
  • b
    balibob
    Nasdaq down a whopping 28% the past 6 months. The one bright spot in my portfolio.. DVAX..
    Bullish
  • L
    Lynn
    Clover up 30% now!
  • b
    balibob
    GOOG down 3.5%, AMZN down 7% .... With the bad retail news everything tanked...
    DVAX showed some true resilience ...
    Bullish
  • T
    Terry
    Nice gain...nice volume. Something is up...this can't just be S&P inclusion. It will be interesting to see what the short interest is at month's end.
  • A
    A1
    I Hope There is News...

    lol

    GL

    A1
  • e
    ecobiz
    The way Dynavax is trading any Nasdaq recovery will send us green very quickly...
  • D
    D
    Patience is a virtue indeed. Gosh, it's good to be back on the right track after 6 long months of miserable manipulation & bear market. 🙏🙌
    Bullish
  • R
    RogerR
    Published: 17 May 2022
    Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study

    During the 6-month follow-up after the booster, the rate of decline of neutralizing antibody level was much less than that after the second dose. Three doses of MVC-COV1901 also improved antibody-mediated neutralization of Alpha, Beta, and Delta variants as well as the Omicron variant pseudovirus.
    Conclusion
    Our data showed increased persistence of neutralizing antibodies and enhancement of immunogenicity against VoCs offered after a third dose of MVC-COV1901.
  • A
    A1
    KEY TAKEAWAYS
    The S&P 600 is a benchmark index for small-cap stocks published by Standard and Poor's.
    Stocks must have a market cap of $850 million to $3.6 billion, which also prevents overlap with S&P's larger cap indices.
    Several index ETFs and mutual funds allow investors to track the performance of the S&P 600 small-cap index.
    The main reason to invest in small caps is that they have more room to grow than large caps.
    Small-cap stocks are not as closely followed by professional analysts, allowing investors to “get in” on these companies while they’re flying under Wall Street’s radar.
    Small-cap stocks have different characteristics than mid-cap and large-cap stocks, giving small-cap stocks significant diversification benefits.
    Limitations to investing in the S&P 600 include volatility risk, business risk, liquidity risk, and a lack of analyst coverage.

    GL

    A1
  • J
    James
    Clover is up 44%. Valneva is up 11% pre-market. Covid numbers are up huge across the globe.
    Bullish
  • e
    ecobiz
    Dynavax running strongly against the market the past few days, something big is coming...
Advertisement
Advertisement